Zacks Investment Research on MSN
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
Shares of Ovid Therapeutics OVID rallied 39.2% primarily driven by the encouraging top-line data readout from an early-stage ...
“Future research will help clarify whether long-term music practice can strengthen the brain’s ability to process rhythm ...
ALTO-101 is an investigational phosphodiesterase-4 (PDE4) inhibitor delivered via a transdermal patch. Inhibition of the PDE4 enzyme is expected to enhance neural circuits and improve cognitive ...
Age-related differences in cortical aperiodic signals can be driven by cardiac influences, emphasizing the need to control for cardiac contributions in studies interpreting cortically measured ...
A Simon Fraser University-led clinical research study is evaluating how advanced brain imaging could improve epilepsy surgery in British Columbia. Epilepsy affects more than 50,000 people in B.C., ...
ANAVEX3-71-SZ-001 achieved its primary endpoint demonstrating safety and tolerability in adults with schizophrenia Encouraging trends observed in biomarkers support continued development NEW YORK, Oct ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback